Tarsus Pharmaceuticals, Inc.
TARS
$69.20
$0.320.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -18.55M | -6.97M | -8.37M | -12.59M | -20.34M |
| Total Depreciation and Amortization | 1.00M | 437.00K | 443.00K | 460.00K | 453.00K |
| Total Amortization of Deferred Charges | 166.00K | 159.00K | 156.00K | 152.00K | 146.00K |
| Total Other Non-Cash Items | 9.98M | 11.20M | 13.53M | 10.90M | 6.71M |
| Change in Net Operating Assets | 68.63M | -29.48M | 13.58M | 19.33M | -16.36M |
| Cash from Operations | 61.22M | -24.65M | 19.33M | 18.26M | -29.39M |
| Capital Expenditure | -4.07M | -5.82M | -6.36M | -1.91M | -1.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 41.95M | -52.74M | 55.63M | -2.83M | -50.70M |
| Cash from Investing | 37.88M | -58.56M | 49.27M | -4.74M | -51.70M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.30M | 1.20M | 2.31M | 2.56M | 1.95M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3.30M | 1.20M | 2.31M | 2.56M | 1.95M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.40M | -82.01M | 70.92M | 16.08M | -79.14M |